Document 2989
 DOCN  M94A2989
 TI    Testicular germ-cell tumors (GCT) in 23 patients (PTS) with HIV
       infection. GICAT (Italian Cooperative Group on AIDS and Tumors).
 DT    9412
 AU    Bernardi D; Errante D; Vaccher E; Tumolo S; Spina M; Nasti G; Marini B;
       Repetto L; Pizzoccaro G; Monfardini S; et al; Centro di Riferimento
       Oncologico, Aviano, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):179 (abstract no. PB0143). Unique
       Identifier : AIDSLINE ICA10/94369586
 AB    Between November 1986 and January 1994, 23 cases of GCT were observed
       within the GICAT. Thirteen pts had seminoma (SGCT) and 10 non seminoma
       (NSGCT). Sixteen were IVDUs, 3 homosexuals, 2 IVDU+homosexual, 1
       hemophiliac and 1 with unknown risk factor. At diagnosis 1 (4.3%)
       patient had AIDS, 5 (21.7%) pts ARC, 4 (17.4%) PGL and the other cases
       (56.5%) were asymptomatic. The median number of CD4+ cells was 200/mmc
       for SGCT and 332/mmc for NSGCT. Ten of 13 pts with stage I and II SGCT
       received infradiaphragmatic irradiation as primary treatment after
       surgery, and 2 pts refused therapy. One patient with advanced disease
       treated with cisplatin, VP-16 and bleomycin (PEB) achieved CR and died
       of AIDS after 12 months. Out of 12 evaluable pts, 5 pts are alive (4 in
       CR and 1 in PD) with a median survival of 24 months, 4 died of AIDS (all
       of them had no evidence of disease), 1 patient died of accidental reason
       (after 24 months from diagnosis), 1 patient died of progression of
       disease after 38 months from diagnosis, 1 was lost to follow up. Out of
       10 pts with NSGCT, 2 cases with stage I refused therapy and were lost to
       follow up. Of the 2 other pts with stage II, 1 underwent retroperitoneal
       lymphnode dissection, was treated with chemotherapy (PEB x 3 cycles) and
       died of AIDS after 47 months from diagnosis, while the other one after
       diagnosis was lost to follow up. Five pts with advanced disease treated
       with PEB for 3-4 cycles achieved a CR (median duration 39 months); three
       of these patients died of AIDS with no evidence of disease, 1 patient is
       alive after 35 months and 1 patient relapsed after 5 months and died of
       progressive disease. A PR was obtained in a patient with PVB. PEB was
       overall well tolerated with no further development of opportunistic
       infections. All pts refusing therapy and lost to follow up were IVDUs.
       In conclusion, pts with GCT can be offered standard oncological therapy
       with similar results to those of the general population, but
       antiretroviral therapy should also be applied in a combined approach to
       better control the underlying HIV infection.
 DE    Antineoplastic Agents, Combined/THERAPEUTIC USE  Cause of Death
       Combined Modality Therapy  Follow-Up Studies  Human  HIV
       Infections/MORTALITY/PATHOLOGY/*THERAPY  Male  Neoplasm Staging
       Neoplasms, Germ Cell and Embryonal/MORTALITY/PATHOLOGY/*THERAPY
       Seminoma/MORTALITY/PATHOLOGY/*THERAPY  Support, Non-U.S. Gov't  Survival
       Rate  Testicular Neoplasms/MORTALITY/PATHOLOGY/*THERAPY  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).